Form 4: Inari Medical Chief Medical Officer Thomas Tu Reports Transaction Following Merger with Stryker Corporation

Thomas Tu, Chief Medical Officer of Inari Medical, reports the cancellation and conversion of stock and options into cash following the merger with Stryker Corporation on February 19, 2025.

Summary

• This Form 4 filing reports changes in beneficial ownership for Thomas Tu, Chief Medical Officer of Inari Medical, Inc.
• The filing is triggered by the merger of Inari Medical with Stryker Corporation, which became effective on February 19, 2025.
• As a result of the merger, Inari Medical became a wholly-owned subsidiary of Stryker Corporation.
• Each outstanding share of Inari Medical common stock was cancelled and converted into the right to receive $80.00 in cash.
• Restricted stock units (RSUs) were also cancelled and converted into the right to receive cash based on the merger consideration.
• Stock options, both vested and unvested, were cancelled and converted into the right to receive cash based on the difference between the merger consideration and the exercise price.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the merger provides a defined cash payout to shareholders and option holders. The completion of the merger removes uncertainty for Inari Medical's investors.

Positives

• The merger provides a cash payout to shareholders, RSU holders, and option holders of Inari Medical.
• Shareholders received $80.00 per share.

Future Outlook

The document does not contain forward-looking statements beyond the completion of the merger.

Industry Context

The acquisition of Inari Medical by Stryker Corporation reflects a trend of consolidation in the medical device industry, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach.

Comparison to Industry Standards

• Mergers and acquisitions are common in the medical device industry, with valuations varying based on factors like growth rate, profitability, and market share.
• Comparable transactions would include acquisitions of companies specializing in vascular therapies and devices.
• The $80 per share cash consideration should be compared to the trading multiples of other medical device companies to assess the fairness of the deal.

Stakeholder Impact

• Shareholders receive $80.00 per share in cash.
• Employees may experience changes as Inari Medical integrates into Stryker Corporation.
• Customers may see changes in product offerings and support as a result of the merger.

Key Dates

Keywords

Merger, Inari Medical, Stryker Corporation, Form 4, Beneficial Ownership, Thomas Tu, Chief Medical Officer, Stock Options, RSUs, Cash Consideration